| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers A > Headlines for AlphaRx Inc. > News item |
AlphaRx: Data show ALRX IM comparable with less toxicity than other eye inflammation treatments
By E. Janene Geiss
Philadelphia, Jan. 17 - AlphaRx Inc. said toxicology data for ALRX IM, the active ingredient in Binoxan, has shown to have comparable biological activity, less toxicity and more soluability than Indomethacin and existing non-steroidal therapy.
ALRX IM, an Indomethacin ester, has increased permeability and correspondingly higher efficacy in treating ocular disorders, according to a company news release.
ALRX IM breaks down into Indomethacin and its ester in equal parts in vivo. Indomethacin has superior anti-inflammatory, analgesic and antipyretic properties and is normally administered in capsular form for the treatment of systemic inflammatory diseases such as arthritis, muscle pain and tendinitis, officials said.
The sodium salt of Indomethacin may be injected intravenously or used topically for treatment of inflammatory conditions of the eye, officials said.
Binoxan is a topical, non-acidic, non-steroidal anti-inflammatory pro-drug in a colloidal formulation, intended for the treatment of ocular inflammation, eye pain and photophobia.
Based upon prescription data compiled by IMS Health, it is estimated that more than 8.6 million prescriptions are written annually in the United States for topical ophthalmic anti-inflammatory agents, with sales in excess of $400 million.
Based in Markham, Ont., AlphaRx is an emerging biopharmaceutical company using proprietary drug delivery technology to develop new formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.